Biomarker & Intervention Discovery

Multiple Myeloma

This page lists 12 druggable gene targets, 53 approved or trial-tested drug candidates and 15 recent clinical trials for Multiple Myeloma, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionEssentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once…
Best-intervention remissionDaratumumab + VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) induction + autologous SCT: 66%…
Gap sizeModerate — outcomes dramatically improved but cure remains elusive; CAR-T access critical unmet need
Primary barrieraccess + biological
Full remission profile →
Research Tracker Chronic Disease Interventions Multiple Myeloma

Remission & chronicity

Spontaneous remission
Essentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once symptomatic
Best-intervention remission
Daratumumab + VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) induction + autologous SCT: 66% MRD-negative at 24 months (PERSEUS); CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel): 71-75% overall response, 28-33% CR in heavily pretreated patients; 5-year survival now ~55% (vs ~20% in 2000)
Gap size
Moderate — outcomes dramatically improved but cure remains elusive; CAR-T access critical unmet need
Primary barrier
access + biological
BCMA-targeted CAR-T therapy is transformative but manufacturing delays (6+ weeks), $420K+ cost, and limited centre access restrict use; bispecific antibodies (teclistamab) offer alternative; a functional cure remains an aspiration not a reality for most patients

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CD38 203CRBN 151FGFR3 217GPRC5D 1HDAC6 233IKZF1 11IKZF3 37KRAS 233PSMB5 167SLAMF7 3TNFRSF17 19XPO1 151

CD38

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ANTI-CD38 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
MEZAGITAMAB ~ modulates Mechanistic DGIdb
THROMBIN ALFA ? unclear Mechanistic DGIdb
ISATUXIMAB ? unclear Mechanistic DGIdb
DARATUMUMAB ↓ inhibits Mechanistic DGIdb
HUMAX-IL15 ↓ inhibits Mechanistic DGIdb
MK-0159 ↓ inhibits Mechanistic DGIdb
FELZARTAMAB ↓ inhibits Mechanistic DGIdb
KUROMANIN ↓ inhibits Mechanistic 6300.0 nM (IC50) ChEMBL
DELPHINIDIN ↓ inhibits Mechanistic 14600.0 nM (IC50) ChEMBL
PELARGONIDIN ↓ inhibits Mechanistic 16300.0 nM (IC50) ChEMBL
MALVIDIN ↓ inhibits Mechanistic 17000.0 nM (IC50) ChEMBL
QUERCETAGETINIDIN ↓ inhibits Mechanistic 14200.0 nM (IC50) ChEMBL
PEONIDIN ↓ inhibits Mechanistic 20900.0 nM (IC50) ChEMBL
CYANIDIN ↓ inhibits Mechanistic 21800.0 nM (IC50) ChEMBL
DIOSMETINIDIN ↓ inhibits Mechanistic 32100.0 nM (IC50) ChEMBL
PETUNIDIN ↓ inhibits Mechanistic 39200.0 nM (IC50) ChEMBL
FISETINIDIN ↓ inhibits Mechanistic 70300.0 nM (IC50) ChEMBL
LUTEOLIN ↓ inhibits Mechanistic 8200.0 nM (IC50) ChEMBL
MYRICETIN ↓ inhibits Mechanistic 24800.0 nM (IC50) ChEMBL
QUERCETIN ↓ inhibits Mechanistic 37900.0 nM (IC50) ChEMBL
ROBINETIN ↓ inhibits Mechanistic 37900.0 nM (IC50) ChEMBL
QUERCETAGETIN ↓ inhibits Mechanistic 48600.0 nM (IC50) ChEMBL
LUTEOLINIDIN ↓ inhibits Mechanistic 6000.0 nM (IC50) ChEMBL
CHEMBL3342444 ↓ inhibits Mechanistic 3300.0 nM (IC50) ChEMBL
CHEMBL3342440 ↓ inhibits Mechanistic 6400.0 nM (IC50) ChEMBL
CHEMBL3342442 ↓ inhibits Mechanistic 33000.0 nM (IC50) ChEMBL
CHEMBL3342443 ↓ inhibits Mechanistic 27000.0 nM (IC50) ChEMBL
CHEMBL3422364 ↓ inhibits Mechanistic 14000.0 nM (IC50) ChEMBL
CHEMBL3422366 ↓ inhibits Mechanistic 26000.0 nM (IC50) ChEMBL
CHEMBL3426029 ↓ inhibits Mechanistic 55.0 nM (IC50) ChEMBL
CHEMBL3426030 ↓ inhibits Mechanistic 89.0 nM (IC50) ChEMBL
CHEMBL3426031 ↓ inhibits Mechanistic 52.0 nM (IC50) ChEMBL
CHEMBL3426032 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3426033 ↓ inhibits Mechanistic 3.9 nM (IC50) ChEMBL
CHEMBL3426034 ↓ inhibits Mechanistic 7.3 nM (IC50) ChEMBL
CHEMBL3426035 ↓ inhibits Mechanistic 10.0 nM (IC50) ChEMBL
CHEMBL3426036 ↓ inhibits Mechanistic 54.0 nM (IC50) ChEMBL
CHEMBL3426037 ↓ inhibits Mechanistic 3.8 nM (IC50) ChEMBL
CHEMBL3426038 ↓ inhibits Mechanistic 13.0 nM (IC50) ChEMBL

Showing top 40 of 203 agents ranked by evidence tier.

CRBN

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
IBERDOMIDE ~ modulates Mechanistic 60.0 nM (IC50) DGIdb
GOLCADOMIDE ? unclear Mechanistic DGIdb
POMALIDOMIDE ↓ inhibits Mechanistic 1200.0 nM (IC50) DGIdb
MG-277 ? unclear Mechanistic DGIdb
LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE ~ modulates Mechanistic DGIdb
THALIDOMIDE ↓ inhibits Mechanistic 29900.0 nM (IC50) DGIdb
TX-16 ? unclear Mechanistic DGIdb
AK-2292 ? unclear Mechanistic DGIdb
LENALIDOMIDE ↓ inhibits Mechanistic 1500.0 nM (IC50) DGIdb
AVADOMIDE ? unclear Mechanistic 38700.0 nM (IC50) DGIdb
DBRD9 ? unclear Mechanistic DGIdb
TL12-186 ? unclear Mechanistic DGIdb
SJ995973 ↓ inhibits Mechanistic DGIdb
CBPD-268 ? unclear Mechanistic DGIdb
MEZIGDOMIDE ? unclear Mechanistic DGIdb
SK5527 ? unclear Mechanistic DGIdb
SB-405483 ~ modulates Mechanistic DGIdb
MS40 ? unclear Mechanistic DGIdb
DTAG-13 ? unclear Mechanistic DGIdb
PTD10 ? unclear Mechanistic DGIdb
MD-222 ? unclear Mechanistic DGIdb
NVP-DKY709 ? unclear Mechanistic DGIdb
CHEMBL3764647 ↓ inhibits Mechanistic 7900.0 nM (Kd) ChEMBL
SUCCINIMIDE ↓ inhibits Mechanistic 34500.0 nM (IC50) ChEMBL
CHEMBL4449512 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL4436772 ↓ inhibits Mechanistic 5.5 nM (IC50) ChEMBL
CHEMBL3693969 ↓ inhibits Mechanistic 1470.0 nM (IC50) ChEMBL
CHEMBL4226052 ↓ inhibits Mechanistic 28.0 nM (Kd) ChEMBL
CHEMBL4466169 ↓ inhibits Mechanistic 10000.0 nM (Kd) ChEMBL
CHEMBL4635421 ↓ inhibits Mechanistic 440.0 nM (Ki) ChEMBL
CHEMBL4648907 ↓ inhibits Mechanistic 130.0 nM (Ki) ChEMBL
CHEMBL4645406 ↓ inhibits Mechanistic 970.0 nM (Ki) ChEMBL
CHEMBL4648134 ↓ inhibits Mechanistic 800.0 nM (Ki) ChEMBL
CHEMBL4639892 ↓ inhibits Mechanistic 2200.0 nM (Ki) ChEMBL
DASABUVIR ↓ inhibits Mechanistic 4710.0 nM (Ki) ChEMBL
CHEMBL4758352 ↓ inhibits Mechanistic 67800.0 nM (Ki) ChEMBL
CHEMBL4797970 ↓ inhibits Mechanistic 65700.0 nM (IC50) ChEMBL
CHEMBL4759876 ↓ inhibits Mechanistic 84800.0 nM (IC50) ChEMBL
CHEMBL4798668 ↓ inhibits Mechanistic 1200.0 nM (IC50) ChEMBL
CHEMBL4749646 ↓ inhibits Mechanistic 460.0 nM (IC50) ChEMBL

Showing top 40 of 151 agents ranked by evidence tier.

FGFR3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SEGIGRATINIB ↓ inhibits Mechanistic DGIdb
RABEPRAZOLE ↓ inhibits Mechanistic DGIdb
ORANTINIB ↓ inhibits Mechanistic DGIdb
DABOGRATINIB ↓ inhibits Mechanistic DGIdb
NINTEDANIB ESYLATE ↓ inhibits Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
VOFATAMAB ? unclear Mechanistic DGIdb
INFIGRATINIB ↓ inhibits Mechanistic DGIdb
FEXAGRATINIB ↓ inhibits Mechanistic DGIdb
DERAZANTINIB ↓ inhibits Mechanistic DGIdb
LY-2874455 ↓ inhibits Mechanistic DGIdb
ROGARATINIB ↓ inhibits Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
TOZASERTIB ? unclear Mechanistic 860.0 nM (Kd) DGIdb
CETRELIMAB ? unclear Mechanistic DGIdb
AVUTOMETINIB ? unclear Mechanistic DGIdb
PAZOPANIB HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ENTRECTINIB ? unclear Mechanistic 158.49 nM (Ki) DGIdb
ENMD-981693 ↓ inhibits Mechanistic DGIdb
ENMD-2076 ↓ inhibits Mechanistic DGIdb
BRIVANIB ↓ inhibits Mechanistic 160.0 nM (Kd) DGIdb
PEMIGATINIB ↓ inhibits Mechanistic DGIdb
CP-547632 ? unclear Mechanistic DGIdb
NVP-TAE684 ? unclear Mechanistic DGIdb
MLN-8054 ? unclear Mechanistic 1200.0 nM (Kd) DGIdb
COMPOUND 29 [PMID: 36356320] ↓ inhibits Mechanistic DGIdb
LY2874455 ↓ inhibits Mechanistic DGIdb
ZOLIGRATINIB ? unclear Mechanistic DGIdb
ASP5878 ↓ inhibits Mechanistic DGIdb
TASURGRATINIB ? unclear Mechanistic DGIdb
MASITINIB ↓ inhibits Mechanistic DGIdb
PONATINIB ↓ inhibits Mechanistic DGIdb
TRAFERMIN ? unclear Mechanistic DGIdb
S-49076 ? unclear Mechanistic DGIdb
GEFITINIB ? unclear Mechanistic DGIdb
PALIFERMIN ? unclear Mechanistic DGIdb
SINTILIMAB ? unclear Mechanistic DGIdb
PICTILISIB ? unclear Mechanistic DGIdb
FGFR INHIBITOR CPL304110 ? unclear Mechanistic DGIdb
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb

Showing top 40 of 217 agents ranked by evidence tier.

GPRC5D

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TALQUETAMAB ~ modulates Mechanistic DGIdb

HDAC6

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ABEXINOSTAT ↓ inhibits Mechanistic DGIdb
TRICHOSTATIN A ↓ inhibits Mechanistic DGIdb
PHENYLBUTYRYLHYDROXAMIC ACID ? unclear Mechanistic DGIdb
KA2507 ↓ inhibits Mechanistic DGIdb
BML-281 ↓ inhibits Mechanistic DGIdb
BENZOHYDROXAMATE ? unclear Mechanistic DGIdb
ROMIDEPSIN ↓ inhibits Mechanistic 14000.0 nM (IC50) DGIdb
VORINOSTAT ↓ inhibits Mechanistic 100.0 nM (IC50) DGIdb
COMPOUND 25AP [PMID: 37796543] ↓ inhibits Mechanistic DGIdb
ENTINOSTAT ↓ inhibits Mechanistic DGIdb
APICIDIN ? unclear Mechanistic 4300.0 nM (IC50) DGIdb
GIVINOSTAT ↓ inhibits Mechanistic DGIdb
INHIBITOR M9 [PMID: 38236416] ↓ inhibits Mechanistic DGIdb
BUFEXAMAC ↓ inhibits Mechanistic DGIdb
VALPROPYLHYDROXAMIC ACID ? unclear Mechanistic DGIdb
PRACINOSTAT ? unclear Mechanistic DGIdb
AR-42 ? unclear Mechanistic DGIdb
FIMEPINOSTAT ↓ inhibits Mechanistic DGIdb
SCRIPTAID ↓ inhibits Mechanistic DGIdb
MARBOSTAT-100 ↓ inhibits Mechanistic DGIdb
CITARINOSTAT ↓ inhibits Mechanistic DGIdb
SUPRASTAT ↓ inhibits Mechanistic DGIdb
QUISINOSTAT ↓ inhibits Mechanistic DGIdb
HINOKITIOL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL324053 ? unclear Mechanistic DGIdb
TYA-018 ↓ inhibits Mechanistic DGIdb
RICOLINOSTAT ↓ inhibits Mechanistic DGIdb
RESMINOSTAT ↓ inhibits Mechanistic DGIdb
SS-208 ↓ inhibits Mechanistic DGIdb
URSOLIC ACID ? unclear Mechanistic DGIdb
COMPOUND 23F [ZHANG ET AL., 2025] ↓ inhibits Mechanistic DGIdb
SANTACRUZAMATE A ↓ inhibits Mechanistic DGIdb
LARGAZOLE ? unclear Mechanistic DGIdb
BUTYRYLHYDROXAMIC ACID ? unclear Mechanistic DGIdb
PSAMMAPLIN A ? unclear Mechanistic DGIdb
BUTYRIC ACID ? unclear Mechanistic DGIdb
CUDC-101 ↓ inhibits Mechanistic DGIdb
VALPROIC ACID ? unclear Mechanistic DGIdb
CHR-3996 ↓ inhibits Mechanistic DGIdb
KA1010 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

IKZF1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DAUNORUBICIN LIPOSOMAL ? unclear Mechanistic DGIdb
IMATINIB ? unclear Mechanistic DGIdb
FLUDARABINE ? unclear Mechanistic DGIdb
METHOTREXATE ? unclear Mechanistic DGIdb
CYTARABINE ? unclear Mechanistic DGIdb
IBERDOMIDE ↑ activates Mechanistic 1.0 nM (EC50) ChEMBL
POMALIDOMIDE ↑ activates Mechanistic 24.0 nM (EC50) ChEMBL
LENALIDOMIDE ↑ activates Mechanistic 67.0 nM (EC50) ChEMBL
CHEMBL5531974 ↑ activates Mechanistic 120.0 nM (EC50) ChEMBL
CHEMBL6074489 ↑ activates Mechanistic 35.0 nM (EC50) ChEMBL
CHEMBL6078004 ↑ activates Mechanistic 650.0 nM (EC50) ChEMBL

IKZF3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic DGIdb
IBERDOMIDE ↑ activates Mechanistic 0.5 nM (EC50) ChEMBL
POMALIDOMIDE ↑ activates Mechanistic 22.0 nM (EC50) ChEMBL
LENALIDOMIDE ↑ activates Mechanistic 87.0 nM (EC50) ChEMBL
CHEMBL4645677 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4640365 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4638224 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4641034 ↑ activates Mechanistic 0.2 nM (EC50) ChEMBL
CHEMBL4645692 ↑ activates Mechanistic 0.3 nM (EC50) ChEMBL
CHEMBL4642904 ↑ activates Mechanistic 0.2 nM (EC50) ChEMBL
CHEMBL4636670 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4647512 ↑ activates Mechanistic 0.5 nM (EC50) ChEMBL
CHEMBL4647905 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4645564 ↑ activates Mechanistic 2.4 nM (EC50) ChEMBL
CHEMBL4644747 ↑ activates Mechanistic 2.1 nM (EC50) ChEMBL
CHEMBL4642316 ↑ activates Mechanistic 3.3 nM (EC50) ChEMBL
CHEMBL4645905 ↑ activates Mechanistic 1.5 nM (EC50) ChEMBL
CHEMBL4634342 ↑ activates Mechanistic 0.5 nM (EC50) ChEMBL
CHEMBL4647587 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4642197 ↑ activates Mechanistic 0.3 nM (EC50) ChEMBL
CHEMBL4634712 ↑ activates Mechanistic 0.7 nM (EC50) ChEMBL
CHEMBL4642361 ↑ activates Mechanistic 0.4 nM (EC50) ChEMBL
CHEMBL4639846 ↑ activates Mechanistic 0.4 nM (EC50) ChEMBL
CHEMBL4642706 ↑ activates Mechanistic 1.0 nM (EC50) ChEMBL
CHEMBL4637801 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4642035 ↑ activates Mechanistic 3.0 nM (EC50) ChEMBL
CHEMBL4638669 ↑ activates Mechanistic 7.5 nM (EC50) ChEMBL
CHEMBL4645982 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4641342 ↑ activates Mechanistic 0.6 nM (EC50) ChEMBL
CHEMBL4646021 ↑ activates Mechanistic 0.3 nM (EC50) ChEMBL
CHEMBL4647343 ↑ activates Mechanistic 0.5 nM (EC50) ChEMBL
CHEMBL4643542 ↑ activates Mechanistic 1.0 nM (EC50) ChEMBL
CHEMBL4636184 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4648954 ↑ activates Mechanistic 0.3 nM (EC50) ChEMBL
CHEMBL4644660 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4637622 ↑ activates Mechanistic 0.1 nM (EC50) ChEMBL
CHEMBL4645264 ↑ activates Mechanistic 0.6 nM (EC50) ChEMBL

KRAS

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GEMCITABINE ? unclear Mechanistic DGIdb
VEDROPREVIR ↓ inhibits Mechanistic DGIdb
COBIMETINIB ? unclear Mechanistic DGIdb
BEVACIZUMAB ? unclear Mechanistic DGIdb
RAS PEPTIDE CANCER VACCINE ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
SOTORASIB ? unclear Mechanistic 68.0 nM (IC50) DGIdb
AMG410 ~ modulates Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
PIMASERTIB ? unclear Mechanistic DGIdb
METFORMIN ? unclear Mechanistic DGIdb
TIZATERKIB ? unclear Mechanistic DGIdb
GARSORASIB ↓ inhibits Mechanistic DGIdb
CAPECITABINE ? unclear Mechanistic DGIdb
ENCORAFENIB ? unclear Mechanistic DGIdb
DACTOLISIB ? unclear Mechanistic DGIdb
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
PICTILISIB ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
ARS-1620 ↓ inhibits Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
COMPOUND 25 [PMID: 32023060] ↓ inhibits Mechanistic DGIdb
DANOPREVIR ↓ inhibits Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
MUC1-TARGETED PEPTIDE GO-203-2C ? unclear Mechanistic DGIdb
THERAPEUTIC TUMOR INFILTRATING LYMPHOCYTES ? unclear Mechanistic DGIdb
AZACITIDINE ? unclear Mechanistic DGIdb
B-RAF/VEGFR-2 INHIBITOR RAF265 ? unclear Mechanistic DGIdb
PARITAPREVIR ↓ inhibits Mechanistic DGIdb
VANIPREVIR ↓ inhibits Mechanistic DGIdb
DUAL IGF-1R/INSR INHIBITOR BMS-754807 ? unclear Mechanistic DGIdb
SORAFENIB ? unclear Mechanistic DGIdb
CILUPREVIR ↓ inhibits Mechanistic DGIdb
TRASTUZUMAB ? unclear Mechanistic DGIdb
TEMSIROLIMUS ? unclear Mechanistic DGIdb
DECITABINE ? unclear Mechanistic DGIdb
SALIRASIB ↓ inhibits Mechanistic DGIdb
PHA-665752 ? unclear Mechanistic DGIdb
MITOGEN-ACTIVATED PROTEIN KINASE KINASE INHIBITOR ? unclear Mechanistic DGIdb
SELUMETINIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

PSMB5

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
IXAZOMIB ↓ inhibits Mechanistic 3.4 nM (IC50) DGIdb
BORTEZOMIB ↓ inhibits Mechanistic 7.9 nM (IC50) DGIdb
OPROZOMIB ↓ inhibits Mechanistic 10.0 nM (IC50) DGIdb
WLL-VS ↓ inhibits Mechanistic DGIdb
BELACTOSIN A ? unclear Mechanistic 1440.0 nM (IC50) DGIdb
BORTEZOMIB D-MANNITOL ↓ inhibits Mechanistic DGIdb
MARIZOMIB ↓ inhibits Mechanistic 3.5 nM (IC50) DGIdb
MG-132 ↓ inhibits Mechanistic 3.7 nM (Ki) DGIdb
LACTACYSTIN ? unclear Mechanistic 370.0 nM (IC50) DGIdb
NIC-0102 ↓ inhibits Mechanistic DGIdb
CARFILZOMIB ↓ inhibits Mechanistic DGIdb
ZETOMIPZOMIB ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL490829 ? unclear Mechanistic DGIdb
IXAZOMIB CITRATE ? unclear Mechanistic DGIdb
CHEMBL381735 ↓ inhibits Mechanistic 2.4 nM (IC50) ChEMBL
CHEMBL383529 ↓ inhibits Mechanistic 260.0 nM (IC50) ChEMBL
CHEMBL377532 ↓ inhibits Mechanistic 0.72 nM (Ki) ChEMBL
CHEMBL207336 ↓ inhibits Mechanistic 17.0 nM (IC50) ChEMBL
CHEMBL208015 ↓ inhibits Mechanistic 6.1 nM (IC50) ChEMBL
CHEMBL208019 ↓ inhibits Mechanistic 170.0 nM (IC50) ChEMBL
CHEMBL205687 ↓ inhibits Mechanistic 130.0 nM (Ki) ChEMBL
CHEMBL204518 ↓ inhibits Mechanistic 2500.0 nM (IC50) ChEMBL
CHEMBL207162 ↓ inhibits Mechanistic 2.5 nM (IC50) ChEMBL
CHEMBL206206 ↓ inhibits Mechanistic 2.9 nM (IC50) ChEMBL
CHEMBL204992 ↓ inhibits Mechanistic 1.1 nM (IC50) ChEMBL
CHEMBL207016 ↓ inhibits Mechanistic 2.1 nM (IC50) ChEMBL
CHEMBL376815 ↓ inhibits Mechanistic 6.7 nM (IC50) ChEMBL
CHEMBL381884 ↓ inhibits Mechanistic 430.0 nM (IC50) ChEMBL
CHEMBL207598 ↓ inhibits Mechanistic 0.5 nM (Ki) ChEMBL
CHEMBL207394 ↓ inhibits Mechanistic 21000.0 nM (IC50) ChEMBL
CHEMBL383122 ↓ inhibits Mechanistic 38.0 nM (Ki) ChEMBL
CHEMBL205757 ↓ inhibits Mechanistic 0.51 nM (Ki) ChEMBL
CHEMBL207425 ↓ inhibits Mechanistic 32.0 nM (Ki) ChEMBL
CHEMBL207196 ↓ inhibits Mechanistic 24.0 nM (IC50) ChEMBL
CHEMBL207669 ↓ inhibits Mechanistic 10.0 nM (IC50) ChEMBL
CHEMBL383673 ↓ inhibits Mechanistic 540.0 nM (IC50) ChEMBL
CHEMBL437311 ↓ inhibits Mechanistic 45.0 nM (Ki) ChEMBL
CHEMBL381931 ↓ inhibits Mechanistic 140.0 nM (Ki) ChEMBL
CHEMBL379476 ↓ inhibits Mechanistic 500.0 nM (Ki) ChEMBL
EPOXOMYCIN ↓ inhibits Mechanistic 3.7 nM (IC50) ChEMBL

Showing top 40 of 167 agents ranked by evidence tier.

SLAMF7

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
XBP1-US/XBP1-SP/CD138/CS1 MULTIPEPTIDE VACCINE PVX-410 ? unclear Mechanistic DGIdb
AZINTUXIZUMAB VEDOTIN ~ modulates Mechanistic DGIdb
ELOTUZUMAB ↓ inhibits Mechanistic DGIdb

TNFRSF17

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CILTACABTAGENE AUTOLEUCEL ? unclear Mechanistic DGIdb
IDECABTAGENE VICLEUCEL ? unclear Mechanistic DGIdb
LINVOSELTAMAB ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-BCMA-CAR-EXPRESSING CD4+/CD8+ T-LYMPHOCYTES FCARH143 ? unclear Mechanistic DGIdb
P-BCMA-101 ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-BCMA-CAR-MRNA-TRANSFECTED CD8+ T-LYMPHOCYTES ? unclear Mechanistic DGIdb
KITE-585 ? unclear Mechanistic DGIdb
APRIL ? unclear Mechanistic DGIdb
ORVACABTAGENE AUTOLEUCEL ? unclear Mechanistic DGIdb
ELRANATAMAB ~ modulates Mechanistic DGIdb
PACANALOTAMAB ? unclear Mechanistic DGIdb
TECLISTAMAB ~ modulates Mechanistic DGIdb
BELANTAMAB MAFODOTIN ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-BCMA-CAR-4-1BB-CD3ZETA-EXPRESSING MEMORY T-LYMPHOCYTES BB21217 ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-BCMA-CAR-4-1BB-CD3ZETA-EXPRESSING T-CELLS C-CAR088 ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-BCMA-CAR-TCRZ/4-1BB-EXPRESSING T-LYMPHOCYTES CART-BCMA ? unclear Mechanistic DGIdb
AUTOLOGOUS BCMA/TACI-TARGETED CAR T CELLS AUTO2 ? unclear Mechanistic DGIdb
BAFF ? unclear Mechanistic DGIdb
ANTI-BCMA CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb

XPO1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
VERDINEXOR ↓ inhibits Mechanistic 24.0 nM (EC50) DGIdb
SELINEXOR ↓ inhibits Mechanistic 18.74 nM (Kd) DGIdb
ELTANEXOR ↓ inhibits Mechanistic DGIdb
LEPTOMYCIN B ↓ inhibits Mechanistic 1.0 nM (IC50) DGIdb
FELEZONEXOR ? unclear Mechanistic DGIdb
GONIOTHALAMIN ? unclear Mechanistic DGIdb
RIFAMPIN ? unclear Mechanistic DGIdb
OSTHOLE ? unclear Mechanistic 1600.0 nM (IC50) DGIdb
CHEMBL1084286 ↓ inhibits Mechanistic 6400.0 nM (IC50) ChEMBL
CHEMBL3929869 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3891836 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3964319 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3896208 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3899053 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3951325 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3929349 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3919410 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3895766 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3893042 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3911673 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3911830 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3914451 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3890257 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3928302 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3925662 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3898004 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3908175 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3915859 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3956187 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3904126 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL4088268 ↓ inhibits Mechanistic 10.0 nM (IC50) ChEMBL
CHEMBL4077955 ↓ inhibits Mechanistic 25.0 nM (IC50) ChEMBL
CHEMBL4277221 ↑ activates Mechanistic 900.0 nM (EC50) ChEMBL
CHEMBL4293588 ↑ activates Mechanistic 1800.0 nM (EC50) ChEMBL
CHEMBL4278766 ↑ activates Mechanistic 3800.0 nM (EC50) ChEMBL
CHEMBL4282126 ↑ activates Mechanistic 1800.0 nM (EC50) ChEMBL
CHEMBL4283174 ↑ activates Mechanistic 900.0 nM (EC50) ChEMBL
CHEMBL4294538 ↑ activates Mechanistic 30000.0 nM (EC50) ChEMBL
CHEMBL4294903 ↑ activates Mechanistic 30000.0 nM (EC50) ChEMBL
CHEMBL4280077 ↑ activates Mechanistic 15000.0 nM (EC50) ChEMBL

Showing top 40 of 151 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Multiple Myeloma: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Recruiting
NCT06948084 Phase: 2 Started: 2027-05-22

This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that has not responded to ...

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma Recruiting
NCT07106710 Phase: 2 Started: 2025-08-15

This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with ultra-high-risk multiple myeloma.

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma Recruiting
NCT06465316 Phase: 1 Started: 2024-12-06

This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a gr...

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Recruiting
NCT07609940 Phase: 4 Started: 2026-07-15

This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who have already been treated with at least four lines of treatment for th...

IASO206 in Patients With Relapsed/Refractory Multiple Myeloma Recruiting
NCT07322159 Phase: Early 1 Started: 2026-01-08

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) Recruiting
NCT06953960 Phase: 1/2 Started: 2025-07-23

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in ...

Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma Recruiting
NCT07891923 Phase: 2 Started: 2025-10-28

The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple myeloma (NDMM). The main questions it aims to answer are: 1. Does the modi...

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma Active Not Recruiting
NCT06952478 Phase: 3 Started: 2025-08-12

This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma Recruiting
NCT07106736 Phase: 2 Started: 2025-08-12

This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia Recruiting
NCT07106684 Phase: 2 Started: 2025-08-09

This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with primary plasma cell leukemia.

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant Recruiting
NCT05623020 Phase: 3 Started: 2022-11-10

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior...

18F-Fluciclovine PET/CT in Multiple Myeloma Recruiting
NCT06103838 Phase: 2 Started: 2024-03-25

Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective: To find out if the radiot...

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03761108 Phase: 1/2 Started: 2019-01-23

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research ques...

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma Recruiting
NCT04822337 Phase: 1/2 Started: 2021-05-19

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and t...

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma Recruiting
NCT04973605 Phase: 1/2 Started: 2021-09-16

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination...

Agents Found By Disease-Level Search

Searched directly from “Multiple Myeloma” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 12-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

53 agents shown (approved or with trial evidence) — 41 not found by the gene-target search above.

DexamethasoneNOT in gene-target list

Approved · 15 trials · source: ClinicalTrials.gov, Open Targets
NCT03029234 NCT01478581 NCT07341867

Bortezomib

Approved · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT00514371 NCT07341867 NCT00006184

LENALIDOMIDE

Approved · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT07341867 NCT06932562 NCT01698801

Carfilzomib

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT03029234 NCT02056756 NCT01677858

cyclophosphamideNOT in gene-target list

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00005854 NCT07341867

cyclosporineNOT in gene-target list

Phase 2 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00005854 NCT00112593

fludarabine phosphateNOT in gene-target list

Phase 2 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT01658319 NCT00856388 NCT00112593

melphalanNOT in gene-target list

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00792142 NCT00856388 NCT00006244

busulfanNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00943319 NCT01237951

Pomalidomide

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT07825064 NCT00833833 NCT02103335

Revlimid, Melphalan, Prednisone, ThalidomideNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00961467 NCT00961467

filgrastimNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT02593123

Pembrolizumab

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01953692 NCT07341867

Daratumumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT07341867 NCT06932562

Teclistamab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06100237 NCT06171685

Talquetamab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06100237 NCT07093554

Linvoseltamab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06932562 NCT07455851

Doxorubicin hydrochlorideNOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00006184 NCT00036790

Methotrexate

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00006184 NCT00005854

cytogenetic analysisNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00792142 NCT00898066

fluorescence in situ hybridizationNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00792142 NCT00898066

Lenalidomide, endoxan, prednisoneNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01352338 NCT01352338

mycophenolate mofetilNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00112593 NCT02593123

sodium seleniteNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02184533

NEX-20ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05643248

LNA-i-miR-221NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04811898

Routine Blood Draw - Phase 1 onlyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06224309

anti-BCMA CAR-TNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06793449

ASCTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06793449

methoxyamineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01658319

western blottingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01658319

DNA analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01658319

ibrutinib (PCI-32765)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT01478581

Fludarabine

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00943319

CampathNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00943319

tanespimycinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00514371

Lenalidomide 20 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01953692

Lenalidomide 25 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01953692

Carboplatin

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07341867

PaclitaxelNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07341867

DoxorubicinNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07341867

CevostamabNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07825064

TocilizumabNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07825064

Daratumumab SCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06100237

ABBV-438NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07409246

Ixazomib (MLN9708)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02697383

nivolumab-daratumumabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03184194

nivolumab-daratumumab with low-dose cyclophosphamideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03184194

Cohort 1: Carfilzomib 15 mg/m2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02148913

Cohort 2: Carfilzomib 20 mg/m2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02148913

Cohort 2b: Carfilzomib 20 mg/m2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02148913

Cohort 3b: Carfilzomib 27 mg/m2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02148913

PI3K-beta Inhibitor GSK2636771NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04439188

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.